{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:41:38Z","timestamp":1791333698690,"version":"4.3.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cryptococcosis is an opportunistic fungal infection that primarily affects people with advanced HIV\/AIDS and is an important cause of morbidity and mortality around the globe. By far the most common presentation of the disease is cryptococcal meningitis (CM), which leads to an estimated 15\u201320% of all HIV related deaths worldwide, 75% of which are in sub-Saharan Africa. However, to the best of our knowledge there is quite limited reviewed data on the epidemiology of cryptococcal antigenemia in a large HIV-infected population in resource limited settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Articles published in English irrespective of the time of publication were systematically searched using comprehensive search strings from PubMed\/Medline and SCOPUS. In addition, Google Scholar and Google databases were searched manually for grey literature. Two reviewers independently assessed study eligibility, extracted data, and assessed risk of bias. The pooled prevalence of cryptococcal antigenemia was determined with 95% confidence interval (CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:bold>A<\/jats:bold>\n                      mong 2941 potential citations, we have included 22 studies with a total of 8338 HIV positive individuals. The studies were reported in ten different countries during the year (2007\u20132018). Most of the articles reported the mean CD4 count of the participants below\u00a0100 cells\/\u03bcl. The pooled prevalence of cryptococcal antigenemia at different CD4 count and ART status was at 8% (95%CI: 6\u201310%) (ranged between 1.7 and 33%). Body mass index (BMI) &lt;\u200918.5\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , CD4 count &lt;\u2009100 cells, patients\u00a0presenting with headache and male gender were reported by two or more articles as an important predictors of cryptococcal antigenemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Implementing a targeted screening of HIV patients with low BMI, CD4 count &lt;\u2009100 cells, having headache and males; and treatment for asymptomatic cryptococcal disease should be considered. Additional data is needed to better define the epidemiology of cryptococcal antigenemia and its predictors in resource limited settings in order to optimize the\u00a0prevention, diagnosis, and treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-05129-w","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T14:03:52Z","timestamp":1591884232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cryptococcal antigenemia and its predictors among HIV infected patients in resource limited settings: a systematic review"],"prefix":"10.1186","volume":"20","author":[{"given":"Awoke","family":"Derbie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mekonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimtubezinash","family":"Woldeamanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamrat","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"5129_CR1","unstructured":"UNAIDS data 2019. [cited 4 March 2020]; Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2019-UNAIDS-data_en.pdf."},{"key":"5129_CR2","unstructured":"WHO. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2018 [cited 2018 15 Dec]; Available from: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/260399\/9789241550277-eng.pdf;jsessionid=3DD47D6B4F06AFA32280E2048900A316?sequence=1."},{"issue":"3","key":"5129_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s11904-013-0165-9","volume":"10","author":"AC Meyer","year":"2013","unstructured":"Meyer AC, Jacobson M. Asymptomatic cryptococcemia in resource-limited settings. Curr HIV\/AIDS Rep. 2013;10(3):254\u201363.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"5129_CR4","unstructured":"Lawrence, D.S., T. Boyer-Chammard, and J.N. Jarvis. Emerging concepts in HIV-associated cryptococcal meningitis. Curr Opin Infect Dis, 2018. 30(10): p. 0000000000000514."},{"issue":"4","key":"5129_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","volume":"23","author":"BJ Park","year":"2009","unstructured":"Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS. Aids. 2009;23(4):525\u201330.","journal-title":"Aids"},{"key":"5129_CR6","doi-asserted-by":"crossref","unstructured":"Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr. 2012:59(5).","DOI":"10.1097\/QAI.0b013e31824c837e"},{"key":"5129_CR7","unstructured":"Uptodate. Microbiology and epidemiology of Cryptococcus neoformans infection. 2018 17 Ju 2018 [cited 2018 15 Dec]; Available from: https:\/\/www.uptodate.com\/contents\/microbiology-and-epidemiology-of-cryptococcus-neoformans-infection."},{"key":"5129_CR8","doi-asserted-by":"crossref","unstructured":"Kwon-Chung KJ, Fraser JA, Doering TL, Wang Z, Janbon G, Idnurm A et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med, 2014. 4(7).","DOI":"10.1101\/cshperspect.a019760"},{"key":"5129_CR9","doi-asserted-by":"publisher","unstructured":"Lortholary, O. Management of cryptococcal meningitis in AIDS: the need for specific studies in developing countries: Clin Infect Dis. 2007 Jul 1;45(1):81\u20133. doi: https:\/\/doi.org\/10.1086\/518583. Epub 2007 May 25.","DOI":"10.1086\/518583"},{"key":"5129_CR10","unstructured":"Pescador Ruschel, M.A. And B. Thapa, Meningitis, Cryptococcal. Available from https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK525986\/. ."},{"issue":"2","key":"5129_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4161\/viru.18685","volume":"3","author":"TB Liu","year":"2012","unstructured":"Liu TB, Perlin DS, Xue C. Molecular mechanisms of cryptococcal meningitis. Virulence. 2012;3(2):173\u201381.","journal-title":"Virulence"},{"issue":"1","key":"5129_CR12","first-page":"19","volume":"7","author":"AJ Hamilton","year":"1996","unstructured":"Hamilton AJ, Goodley J. Virulence factors of Cryptococcus neoformans. Curr Top Med Mycol. 1996;7(1):19\u201342.","journal-title":"Curr Top Med Mycol"},{"issue":"3","key":"5129_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11904-010-0052-6","volume":"7","author":"A Jackson","year":"2010","unstructured":"Jackson A, Hosseinipour MC. Management of cryptococcal meningitis in sub-saharan Africa. Curr HIV\/AIDS Rep. 2010;7(3):134\u201342.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"5129_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/CLEP.S38850","volume":"6","author":"DJ Sloan","year":"2014","unstructured":"Sloan DJ, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options. Clin Epidemiol. 2014;6:169\u201382.","journal-title":"Clin Epidemiol"},{"issue":"7","key":"5129_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1473-3099(13)70078-1","volume":"13","author":"A Loyse","year":"2013","unstructured":"Loyse A, Thangaraj H, Easterbrook P, Ford N, Roy M, Chiller T, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis. 2013;13(7):629\u201337.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"5129_CR16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/1545109712459077","volume":"11","author":"JN Jarvis","year":"2012","unstructured":"Jarvis JN, Govender N, Chiller T, Park BJ, Longley N, Meintjes G, et al. Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Phys AIDS Care. 2012;11(6):374\u20139.","journal-title":"J Int Assoc Phys AIDS Care"},{"issue":"2","key":"5129_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s40475-015-0046-y","volume":"2","author":"M Abassi","year":"2015","unstructured":"Abassi M, Boulware DR, Rhein J. Cryptococcal meningitis: diagnosis and management update. Curr Trop Med Rep. 2015;2(2):90\u20139.","journal-title":"Curr Trop Med Rep"},{"issue":"4","key":"5129_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.mycmed.2016.08.007","volume":"26","author":"A Ogouyemi-Hounto","year":"2016","unstructured":"Ogouyemi-Hounto A, Zannou DM, Ayihounton G, Ahouada C, Azon-Kouanou A, Acakpo J, et al. Prevalence and factors associated with cryptococcal antigenemia in HIV-infected patients in Cotonou\/Benin. J Mycol Med. 2016;26(4):391\u20137.","journal-title":"J Mycol Med"},{"issue":"1","key":"5129_CR19","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1186\/1758-2652-15-15","volume":"15","author":"J Oyella","year":"2012","unstructured":"Oyella J, Meya D, Bajunirwe F, Kamya MR. Prevalence and factors associated with cryptococcal antigenemia among severely immunosuppressed HIV-infected adults in Uganda: a cross-sectional study. J Int AIDS Soc. 2012;15(1):1758\u20132652.","journal-title":"J Int AIDS Soc"},{"key":"5129_CR20","doi-asserted-by":"crossref","unstructured":"Magambo KA, Kalluvya SE, Kapoor SW, Seni J, Chofle AA, Fitzgerald DW, et al. Utility of urine and serum lateral flow assays to determine the prevalence and predictors of cryptococcal antigenemia in HIV-positive outpatients beginning antiretroviral therapy in Mwanza, Tanzania. J Int AIDS Soc. 2014:17(19040).","DOI":"10.7448\/IAS.17.1.19040"},{"issue":"6","key":"5129_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/cid\/ciu937","volume":"60","author":"J McKenney","year":"2015","unstructured":"McKenney J, Bauman S, Neary B, Detels R, French A, Margolick J, et al. Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012. Clin Infect Dis. 2015;60(6):959\u201365.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"5129_CR22","doi-asserted-by":"publisher","first-page":"e170554","DOI":"10.1590\/0074-02760170554","volume":"113","author":"C Firacative","year":"2018","unstructured":"Firacative C, Lizarazo J, Illnait-Zaragoz\u00ed MT, Casta\u00f1eda E. The status of cryptococcosis in Latin America. Memorias do Instituto Oswaldo Cruz. 2018;113(7):e170554.","journal-title":"Memorias do Instituto Oswaldo Cruz"},{"key":"5129_CR23","doi-asserted-by":"crossref","unstructured":"Bongomin F, Gago S, Oladele RO, Denning DW. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi, 2017. 3(4).","DOI":"10.3390\/jof3040057"},{"key":"5129_CR24","unstructured":"Group, T.W.B. World Bank Country and Lending Groups. 2018 [cited 2018 18 Dec]; Available from: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups."},{"key":"5129_CR25","doi-asserted-by":"crossref","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. Bmj, 2015. 2(350).","DOI":"10.1136\/bmj.g7647"},{"key":"5129_CR26","unstructured":"Institute, T.J.B. The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews: Checklist for Prevalence Studies. 2017 [cited 2018 1 Aug]; Available from: http:\/\/joannabriggs.org\/research\/critical-appraisal-tools.html."},{"issue":"7","key":"5129_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):21.","journal-title":"PLoS Med"},{"issue":"12","key":"5129_CR28","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/tmi.12790","volume":"21","author":"JE Vidal","year":"2016","unstructured":"Vidal JE, Toniolo C, Paulino A, Colombo A, Dos Anjos MM, da Silva MC, et al. Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in Sao Paulo. Brazil Trop Med Int Health. 2016;21(12):1539\u201344.","journal-title":"Brazil Trop Med Int Health"},{"issue":"1","key":"5129_CR29","doi-asserted-by":"publisher","first-page":"18821","DOI":"10.7448\/IAS.17.1.18821","volume":"17","author":"AR Ganiem","year":"2014","unstructured":"Ganiem AR, Indrati AR, Wisaksana R, Meijerink H, van der Ven A, Alisjahbana B, et al. Asymptomatic cryptococcal antigenemia is associated with mortality among HIV-positive patients in Indonesia. J Int AIDS Soc. 2014;17(1):18821.","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"5129_CR30","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/j.1365-3156.2007.01874.x","volume":"12","author":"CA Liechty","year":"2007","unstructured":"Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, Weidle PJ, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Tropical Med Int Health. 2007;12(8):929\u201335.","journal-title":"Tropical Med Int Health"},{"issue":"10","key":"5129_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075585","volume":"8","author":"T Beyene","year":"2013","unstructured":"Beyene T, Woldeamanuel Y, Asrat D, Ayana G, Boulware DR. Comparison of Cryptococcal Antigenemia between antiretroviral Na\u00efve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia. PLoS One. 2013;8(10):e75585.","journal-title":"PLoS One"},{"issue":"4","key":"5129_CR32","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1086\/655143","volume":"51","author":"DB Meya","year":"2010","unstructured":"Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. Cost-effectiveness of serum Cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count \u2264100 cells\/\u03bcL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51(4):448\u201355.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"5129_CR33","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/tmi.12157","volume":"18","author":"J Rugemalila","year":"2013","unstructured":"Rugemalila J, Maro VP, Kapanda G, Ndaro AJ, Jarvis JN. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay. Tropical Med Int Health. 2013;18(9):1075\u20139.","journal-title":"Tropical Med Int Health"},{"issue":"5","key":"5129_CR34","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/cid\/civ936","volume":"62","author":"N Longley","year":"2016","unstructured":"Longley N, Jarvis JN, Meintjes G, Boulle A, Cross A, Kelly N, et al. Cryptococcal antigen screening in patients initiating ART in South Africa: a prospective cohort study. Clin Infect Dis. 2016;62(5):581\u20137.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"5129_CR35","first-page":"746","volume":"2","author":"K Hailu","year":"2018","unstructured":"Hailu K, Niguse S, Hagos K, Abdulkader M. Cryptococcal antigenemia and associated risk factors among ART-naive and ART-experienced HIV-infected peoples at selected health institutions of Mekelle. Northern Ethiopia Microbiologyopen. 2018;2(10):746.","journal-title":"Northern Ethiopia Microbiologyopen"},{"key":"5129_CR36","doi-asserted-by":"crossref","unstructured":"Letang E, M\u00fcller MC, Ntamatungiro AJ, Kimera N, Faini D, Furrer H et al. Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality. Open Forum Infectious Diseases, 2015. 2(2): p. ofv046-ofv046.","DOI":"10.1093\/ofid\/ofv046"},{"issue":"1","key":"5129_CR37","first-page":"21","volume":"69","author":"AE Christopher","year":"2015","unstructured":"Christopher AE, Richard O, Otibhor A-I. Cryptococcus neoformans infection among human immunodeficiency virus patients on highly active antiretroviral therapy in Benin City. Nigeria NZ J Med Lab Science. 2015;69(1):21\u20133.","journal-title":"Nigeria NZ J Med Lab Science"},{"issue":"3","key":"5129_CR38","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/cid\/civ263","volume":"61","author":"DA Williams","year":"2015","unstructured":"Williams DA, Kiiza T, Kwizera R, Kiggundu R, Velamakanni S, Meya DB, et al. Evaluation of Fingerstick Cryptococcal antigen lateral flow assay in HIV-infected persons: a diagnostic accuracy study. Clin Infect Dis. 2015;61(3):464\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"5129_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1371\/journal.pone.0058377","volume":"8","author":"AS Alemu","year":"2013","unstructured":"Alemu AS, Kempker RR, Tenna A, Smitson C, Berhe N, Fekade D, et al. High prevalence of Cryptococcal antigenemia among HIV-infected patients receiving antiretroviral therapy in Ethiopia. PLoS One. 2013;8(3):4.","journal-title":"PLoS One"},{"issue":"4","key":"5129_CR40","first-page":"6","volume":"28","author":"A Derbie","year":"2018","unstructured":"Derbie A, Ayalew W, Mekonnen D, Alemu M, Mulugeta Y. Magnitude of Cryptococcal Antigenemia among HIV infected patients at a referral hospital. Northwest Ethiopia Ethiop J Health. 2018;28(4):6.","journal-title":"Northwest Ethiopia Ethiop J Health"},{"issue":"4","key":"5129_CR41","doi-asserted-by":"publisher","first-page":"786","DOI":"10.4269\/ajtmh.15-0857","volume":"95","author":"AT Mamuye","year":"2016","unstructured":"Mamuye AT, Bornstein E, Temesgen O, Blumberg HM, Kempker RR. Point-of-care testing for Cryptococcal disease among hospitalized human immunodeficiency virus-infected adults in Ethiopia. Am J Trop Med Hyg. 2016;95(4):786\u201392.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"5129_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1758-2652-15-15","volume":"15","author":"J Oyella","year":"2012","unstructured":"Oyella J, Meya D, Bajunirwe F, Kamya MR. Prevalence and factors associated with cryptococcal antigenemia among severely immunosuppressed HIV-infected adults in Uganda: a cross-sectional study. J Int AIDS Soc. 2012;15(1):15.","journal-title":"J Int AIDS Soc"},{"issue":"10","key":"5129_CR43","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/hiv.12263","volume":"16","author":"PK Drain","year":"2015","unstructured":"Drain PK, Kleene JM, Coleman SM, Losina E, Katz JN, Giddy J, et al. Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu-Natal. HIV Med. 2015;16(10):640\u20134.","journal-title":"HIV Med"},{"issue":"12","key":"5129_CR44","first-page":"481","volume":"87","author":"R Mdodo","year":"2010","unstructured":"Mdodo R, Brown K, Omonge E, Jaoko W, Baddley J, Pappas P, et al. The prevalence, clinical features, risk factors and outcome associated with cryptococcal meningitis in HIV positive patients in Kenya. East Afr Med J. 2010;87(12):481\u20137.","journal-title":"East Afr Med J"},{"issue":"5","key":"5129_CR45","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/QAI.0b013e31811ed32c","volume":"45","author":"R Micol","year":"2007","unstructured":"Micol R, Lortholary O, Sar B, Laureillard D, Ngeth C, Dousset JP, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr. 2007;45(5):555\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"5129_CR46","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1086\/597262","volume":"48","author":"JN Jarvis","year":"2009","unstructured":"Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for Cryptococcal Antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009;48(7):856\u201362.","journal-title":"Clin Infect Dis"},{"issue":"48","key":"5129_CR47","first-page":"1758","volume":"14","author":"BM Wajanga","year":"2011","unstructured":"Wajanga BM, Kalluvya S, Downs JA, Johnson WD, Fitzgerald DW, Peck RN. Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study. J Int AIDS Soc. 2011;14(48):1758\u20132652.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"5129_CR48","doi-asserted-by":"publisher","first-page":"19040","DOI":"10.7448\/IAS.17.1.19040","volume":"17","author":"KA Magambo","year":"2014","unstructured":"Magambo KA, Kalluvya SE, Kapoor SW, Seni J, Chofle AA, Fitzgerald DW, et al. Utility of urine and serum lateral flow assays to determine the prevalence and predictors of cryptococcal antigenemia in HIV-positive outpatients beginning antiretroviral therapy in Mwanza, Tanzania. J Int AIDS Soc. 2014;17(1):19040.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"5129_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrneurol.2016.167","volume":"13","author":"PR Williamson","year":"2017","unstructured":"Williamson PR, Jarvis JN, Panackal AA, Fisher MC, Molloy SF, Loyse A, et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. Nat Rev Neurol. 2017;13(1):13\u201324.","journal-title":"Nat Rev Neurol"},{"key":"5129_CR50","doi-asserted-by":"crossref","unstructured":"Oladele RO, Bongomin F, Gago S, Denning DW. HIV-Associated Cryptococcal Disease in Resource-Limited Settings: A Case for \"Prevention Is Better Than Cure\"? J Fungi, 2017. 3(4).","DOI":"10.3390\/jof3040067"},{"issue":"9","key":"5129_CR51","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1586\/eri.11.86","volume":"9","author":"M Roy","year":"2011","unstructured":"Roy M, Chiller T. Preventing deaths from cryptococcal meningitis: from bench to bedside. Expert Rev Anti-Infect Ther. 2011;9(9):715\u20137.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"471363","key":"5129_CR52","first-page":"471363","volume":"25","author":"S Antinori","year":"2013","unstructured":"Antinori S. New insights into HIV\/AIDS-associated Cryptococcosis. Isrn Aids. 2013;25(471363):471363.","journal-title":"Isrn Aids"},{"issue":"6","key":"5129_CR53","doi-asserted-by":"publisher","first-page":"e0005575","DOI":"10.1371\/journal.pntd.0005575","volume":"11","author":"SF Molloy","year":"2017","unstructured":"Molloy SF, Chiller T, Greene GS, Burry J, Govender NP, Kanyama C, et al. Cryptococcal meningitis: a neglected NTD? PLoS Negl Trop Dis. 2017;11(6):e0005575.","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"5129_CR54","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","volume":"17","author":"R Rajasingham","year":"2017","unstructured":"Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873\u201381.","journal-title":"Lancet Infect Dis"},{"key":"5129_CR55","doi-asserted-by":"crossref","unstructured":"Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C,, et al., CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis. Clin Infect Dis, 2018. 66(suppl_2): p. S152-S159.","DOI":"10.1093\/cid\/cix1143"},{"key":"5129_CR56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/B978-0-444-63849-6.00011-6","volume":"152","author":"A Spec","year":"2018","unstructured":"Spec A, Powderly WG. Cryptococcal meningitis in AIDS. Handb Clin Neurol. 2018;152:139\u201350.","journal-title":"Handb Clin Neurol"},{"key":"5129_CR57","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s40588-016-0035-5","volume":"3","author":"MW Tenforde","year":"2016","unstructured":"Tenforde MW, Wake R, Leeme T, Jarvis JN. HIV-associated Cryptococcal meningitis: bridging the gap between developed and resource-limited settings. Curr Clin Microbiol Rep. 2016;3:92\u2013102.","journal-title":"Curr Clin Microbiol Rep"},{"issue":"4","key":"5129_CR58","doi-asserted-by":"publisher","first-page":"73","DOI":"10.11648\/j.cmr.20160504.12","volume":"5","author":"B Adane","year":"2016","unstructured":"Adane B, Mulu H, Tigist G, Surafel F. Prevalence of Crytpococcal infection in patients clinically diagnosed to have meningitis in Ethiopia. Clinical Medicine Research. 2016;5(4):73\u20136.","journal-title":"Clinical Medicine Research"},{"key":"5129_CR59","doi-asserted-by":"crossref","unstructured":"Thomsen D, Hviid CJ, Honge BL, Medina C, Te DDS, Correira FG et al. Increased mortality among HIV infected patients with cryptococcal antigenemia in Guinea-Bissau. Pan Afr Med J, 2018. 29(18).","DOI":"10.11604\/pamj.2018.29.18.14099"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05129-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05129-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05129-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T19:25:20Z","timestamp":1623353120000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05129-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5129"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05129-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.15642\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.15642\/v2","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"assertion":[{"value":"26 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable in this section.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable in this section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"407"}}